V14-10 MRI/US FUSION GUIDED PROSTATE BIOPSY AND CRYOTHERAPY IN A CLINICAL OFFICE SETTING

Abstract

You have accessJournal of UrologyProstate Oncology II & Testis Oncology & Misc. Oncology (V14)1 Sep 2021V14-10 MRI/US FUSION GUIDED PROSTATE BIOPSY AND CRYOTHERAPY IN A CLINICAL OFFICE SETTING Fernando Bianco, Eusebio Luna, Luanda Perez, Alberto Lopez-Prieto, Edward Gheiler, Ariel Kaufman, Farshad Shafizadeh, Michael Zachareas, Juan Martinez-Salamanca, Gloria Egui-Benatuil, and Michael Kattan Fernando BiancoFernando Bianco More articles by this author , Eusebio LunaEusebio Luna More articles by this author , Luanda PerezLuanda Perez More articles by this author , Alberto Lopez-PrietoAlberto Lopez-Prieto More articles by this author , Edward GheilerEdward Gheiler More articles by this author , Ariel KaufmanAriel Kaufman More articles by this author , Farshad ShafizadehFarshad Shafizadeh More articles by this author , Michael ZachareasMichael Zachareas More articles by this author , Juan Martinez-SalamancaJuan Martinez-Salamanca More articles by this author , Gloria Egui-BenatuilGloria Egui-Benatuil More articles by this author , and Michael KattanMichael Kattan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002111.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The American Cancer Society estimates that 248,530 men (1 out of every 8) will be diagnosed with prostate cancer during 2021. MR/US has brought precision a in diagnosis and opportunity to decrease harm associated to whole gland radical interventions. The interest to develop new ablative therapies has risen as a resource to prevent overtreatment. We have developed a transperineal fusion approach that allows for precise diagnosis and treatment in the office setting under local anesthesia. METHODS: NCT02381990 represents a meticulous prospective registry that aims to characterize outcomes after MR/US Fusion Cryoablation in the office setting. Between 2014 and 2020, 369 patients positive for prostate cancer after MR/US Transperineal Fusion Biopsy (TPFBx) underwent targeted MR/US Transperineal Fusion Cryoablation (TPFTx) across 4 institutions. The video shows a representative case. We present short term outcomes for these patients. RESULTS: The median time from biopsy to treatment for the 369 patient cohort was 6 weeks. All 738 procedures were completed with median times (TPFBx and TPFTx, 24’ and 55’, respectively) and median pain scores (1-10 scale) were 3(TPFBx) and 2(TPFTx). 160 of these patients had TPFTx within during 2020. Of the reminder 209, 173 completed 1-year TPFBx and 57 (32%) were positive. The Gleason groups distribution for those with a 1-year positive biopsy were more favorable than the initial diagnostic TPFBx CONCLUSIONS: MRI/US Fusion prostate biopsies and cryoablation allow targeting prostate cancer lesions in a safe, accurate, and reproducible manner. This approach prevents overtreatment and could be considered an alternative to active surveillance as 68% of patients have no evidence of disease a year after treatment. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1168-e1168 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Fernando Bianco More articles by this author Eusebio Luna More articles by this author Luanda Perez More articles by this author Alberto Lopez-Prieto More articles by this author Edward Gheiler More articles by this author Ariel Kaufman More articles by this author Farshad Shafizadeh More articles by this author Michael Zachareas More articles by this author Juan Martinez-Salamanca More articles by this author Gloria Egui-Benatuil More articles by this author Michael Kattan More articles by this author Expand All Advertisement Loading ...